JP2018501322A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501322A5 JP2018501322A5 JP2017555445A JP2017555445A JP2018501322A5 JP 2018501322 A5 JP2018501322 A5 JP 2018501322A5 JP 2017555445 A JP2017555445 A JP 2017555445A JP 2017555445 A JP2017555445 A JP 2017555445A JP 2018501322 A5 JP2018501322 A5 JP 2018501322A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- standard
- immune response
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 32
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 150000002632 lipids Chemical class 0.000 claims 12
- 108010034143 Inflammasomes Proteins 0.000 claims 10
- 230000028993 immune response Effects 0.000 claims 9
- 230000002163 immunogen Effects 0.000 claims 8
- 230000003213 activating effect Effects 0.000 claims 6
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000028709 inflammatory response Effects 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 241000224489 Amoeba Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000194033 Enterococcus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000588722 Escherichia Species 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 101000735376 Homo sapiens Protocadherin-8 Proteins 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims 1
- PEZXEQJZQAVYCZ-NLMPBQEBSA-N PKODiA-PC Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCC(=O)\C=C\C(O)=O PEZXEQJZQAVYCZ-NLMPBQEBSA-N 0.000 claims 1
- 102100034958 Protocadherin-8 Human genes 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000028996 humoral immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020213210A JP7410845B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2020213211A JP7410846B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562102245P | 2015-01-12 | 2015-01-12 | |
| US62/102,245 | 2015-01-12 | ||
| PCT/US2016/012994 WO2016115097A2 (en) | 2015-01-12 | 2016-01-12 | Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213210A Division JP7410845B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2020213211A Division JP7410846B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018501322A JP2018501322A (ja) | 2018-01-18 |
| JP2018501322A5 true JP2018501322A5 (https=) | 2019-02-28 |
Family
ID=56406560
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555445A Pending JP2018501322A (ja) | 2015-01-12 | 2016-01-12 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2020213210A Active JP7410845B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2020213211A Active JP7410846B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2023015047A Active JP7719816B2 (ja) | 2015-01-12 | 2023-02-03 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2023015026A Active JP7719815B2 (ja) | 2015-01-12 | 2023-02-03 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2025041934A Pending JP2025090801A (ja) | 2015-01-12 | 2025-03-14 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2025041931A Pending JP2025094038A (ja) | 2015-01-12 | 2025-03-14 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213210A Active JP7410845B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2020213211A Active JP7410846B2 (ja) | 2015-01-12 | 2020-12-23 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2023015047A Active JP7719816B2 (ja) | 2015-01-12 | 2023-02-03 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2023015026A Active JP7719815B2 (ja) | 2015-01-12 | 2023-02-03 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2025041934A Pending JP2025090801A (ja) | 2015-01-12 | 2025-03-14 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
| JP2025041931A Pending JP2025094038A (ja) | 2015-01-12 | 2025-03-14 | トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US20180318414A1 (https=) |
| EP (2) | EP4681782A3 (https=) |
| JP (7) | JP2018501322A (https=) |
| AU (2) | AU2021200638B2 (https=) |
| CA (1) | CA2973585A1 (https=) |
| ES (1) | ES3057334T3 (https=) |
| WO (1) | WO2016115097A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180318414A1 (en) | 2015-01-12 | 2018-11-08 | Children's Medical Center Corporation | Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists |
| AU2017356295A1 (en) * | 2016-11-14 | 2019-05-23 | Beth Israel Deaconess Medical Center | Compositions and methods of treating cancer |
| CA3135291A1 (en) * | 2019-03-29 | 2020-10-08 | The Brigham And Women's Hospital, Inc. | Targeted synergistic cancer immunotherapy |
| AU2020363707A1 (en) * | 2019-10-07 | 2022-04-28 | Northwest Biotherapeutics, Inc. | In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response |
| JP7753205B2 (ja) * | 2019-11-18 | 2025-10-14 | ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン | 超活性樹状細胞は養子細胞移植に基づく持続性抗腫瘍免疫を可能にする |
| EP4061409A4 (en) * | 2019-11-18 | 2023-12-27 | Children's Medical Center Corporation | Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy |
| CN114894910B (zh) * | 2022-03-18 | 2023-10-20 | 重庆医科大学附属第一医院 | 1-棕榈酰-2-花生四烯酰-sn-甘油-3-磷酸胆碱检测试剂的新用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5158939A (en) * | 1989-07-21 | 1992-10-27 | Wisconsin Alumni Research Foundation | Method of stimulating the immune systems of animals and compositions useful therefor |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| AU762369B2 (en) | 1998-11-03 | 2003-06-26 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | LPS with reduced toxicity from genetically modified gram negative bacteria |
| WO2004006910A1 (de) * | 2002-07-15 | 2004-01-22 | Norbert Leitinger | Lipidoxidationsprodukte zur hemmung von entzündungen |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| US8961982B2 (en) * | 2005-12-16 | 2015-02-24 | The Regents Of The University Of California | Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer |
| JP2010505883A (ja) * | 2006-10-12 | 2010-02-25 | ザ ユニバーシティー オブ クイーンズランド | 免疫応答を調節するための組成物および方法 |
| WO2011013682A1 (ja) | 2009-07-27 | 2011-02-03 | 株式会社神戸製鋼所 | 配線構造およびその製造方法、並びに配線構造を備えた表示装置 |
| US20130108661A1 (en) | 2010-02-05 | 2013-05-02 | Mount Sinai School Of Medicine | Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells |
| BR112012027745A2 (pt) | 2010-04-27 | 2017-01-10 | Univ Johns Hopkins | método e composição imunogênica para tratamento de neoplásia |
| WO2012177624A2 (en) | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| CN104066706B (zh) * | 2011-12-12 | 2017-12-19 | 脉管生物生长有限公司 | 炎症的治疗 |
| WO2014164699A1 (en) * | 2013-03-11 | 2014-10-09 | The Regents Of The University Of California | Herpes virus vaccines and treatments |
| WO2015091787A1 (en) | 2013-12-18 | 2015-06-25 | Julius-Maximilians-Universität Würzburg | Galactose oxidase treatment of dendritic cells to improve their immunogenicity |
| US20180318414A1 (en) * | 2015-01-12 | 2018-11-08 | Children's Medical Center Corporation | Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists |
| CA2982614A1 (en) | 2015-05-07 | 2016-11-10 | Baylor College Of Medicine | Dendritic cell immunotherapy |
| US10813988B2 (en) | 2016-02-16 | 2020-10-27 | President And Fellows Of Harvard College | Pathogen vaccines and methods of producing and using the same |
| CA3028654A1 (en) | 2016-06-27 | 2018-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Therapeutic antitumor combination of a tlr4 ligand with other treatments |
| WO2018067302A2 (en) | 2016-09-19 | 2018-04-12 | North Western University | Therapeutic effects of cellular delivery of small molecules and macromolecules with liposomal spherical nucleic acids |
| CA3098868A1 (en) | 2018-05-03 | 2019-11-07 | L.E.A.F. Holdings Group Llc | Carotenoid compositions and uses thereof |
| AU2020363707A1 (en) | 2019-10-07 | 2022-04-28 | Northwest Biotherapeutics, Inc. | In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response |
| JP7753205B2 (ja) | 2019-11-18 | 2025-10-14 | ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン | 超活性樹状細胞は養子細胞移植に基づく持続性抗腫瘍免疫を可能にする |
| EP4061409A4 (en) | 2019-11-18 | 2023-12-27 | Children's Medical Center Corporation | Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy |
-
2016
- 2016-01-12 US US15/543,165 patent/US20180318414A1/en not_active Abandoned
- 2016-01-12 EP EP25205526.4A patent/EP4681782A3/en active Pending
- 2016-01-12 CA CA2973585A patent/CA2973585A1/en active Pending
- 2016-01-12 EP EP16737709.2A patent/EP3244923B1/en active Active
- 2016-01-12 WO PCT/US2016/012994 patent/WO2016115097A2/en not_active Ceased
- 2016-01-12 JP JP2017555445A patent/JP2018501322A/ja active Pending
- 2016-01-12 ES ES16737709T patent/ES3057334T3/es active Active
-
2020
- 2020-09-11 US US17/018,038 patent/US11400153B2/en active Active
- 2020-09-11 US US17/018,045 patent/US11351250B2/en active Active
- 2020-12-23 JP JP2020213210A patent/JP7410845B2/ja active Active
- 2020-12-23 JP JP2020213211A patent/JP7410846B2/ja active Active
-
2021
- 2021-02-01 AU AU2021200638A patent/AU2021200638B2/en active Active
-
2022
- 2022-04-26 US US17/730,030 patent/US12070499B2/en active Active
- 2022-05-09 US US17/739,953 patent/US12053522B2/en active Active
-
2023
- 2023-02-03 JP JP2023015047A patent/JP7719816B2/ja active Active
- 2023-02-03 JP JP2023015026A patent/JP7719815B2/ja active Active
-
2024
- 2024-06-18 US US18/746,749 patent/US20240415957A1/en active Pending
- 2024-07-17 US US18/774,985 patent/US20250025552A1/en active Pending
- 2024-09-06 AU AU2024219454A patent/AU2024219454A1/en active Pending
-
2025
- 2025-03-14 JP JP2025041934A patent/JP2025090801A/ja active Pending
- 2025-03-14 JP JP2025041931A patent/JP2025094038A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018501322A5 (https=) | ||
| Tritto et al. | Mechanism of action of licensed vaccine adjuvants | |
| Silva et al. | Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responses | |
| Mori et al. | The vaccine adjuvant alum inhibits IL‐12 by promoting PI 3 kinase signaling while chitosan does not inhibit IL‐12 and enhances T h1 and T h17 responses | |
| WO2009089535A3 (en) | Polypeptide vaccine and vaccination strategy against mycobacterium | |
| Toussi et al. | Immune adjuvant effect of molecularly-defined toll-like receptor ligands | |
| CN106163551B (zh) | 单瓶疫苗制剂 | |
| Plaisance et al. | Effect of antipyretic therapy on the duration of illness in experimental influenza A, Shigella sonnei, and Rickettsia rickettsii infections | |
| HRP20150177T1 (hr) | Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva | |
| HRP20160816T1 (hr) | Upotreba virusa influence i emulzije ulja u vodi kao adjuvansa radi poticanja t-stanica cd4 i/ili poboljšanog odgovora memorijskih b-stanica | |
| WO2009128950A8 (en) | Deletion mutants of flagellin and methods of use | |
| CN104363892A (zh) | 包含tlr4激动剂的改进佐剂制剂及其使用方法 | |
| CN103357010A (zh) | 疫苗组合物 | |
| CY1110764T1 (el) | Πιστοποιηση συναφων με μολυσματικοτητα περιοχων rd1 και rd5 που επιτρεπει την αναπτυξη βελτιωμενων εμβολιων του μ. bovis bcg και μ. microti | |
| Kianmehr et al. | Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice | |
| WO2011106607A3 (en) | Subunit vaccines for herpes viruses and methods of use | |
| JP2010523711A5 (https=) | ||
| Liu et al. | Maintenance and recall of memory T cell populations against tuberculosis: Implications for vaccine design | |
| Rahman et al. | Advances in bacterial lysate immunotherapy for infectious diseases and cancer | |
| JP2012001565A5 (https=) | ||
| RU2010129770A (ru) | Вакцина против гриппа и способ ее получения | |
| RU2016141621A (ru) | Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин | |
| JP2018532742A5 (https=) | ||
| WO2006114680A3 (en) | Vaccine adjuvants | |
| EP4421174A3 (en) | Adjuvant comprising a glycoarchaeol and an immunostimulant |